CD274 and non-small cell lung carcinoma: Our retrospective analysis of 251 unresectable stage III NSCLC patients demonstrated longer OS and PFS with CRT + durvalumab compared to CRT alone in PD-L1 ≥ 1%, but not <1% patients.